Aldeyra to stop noninfectious anterior uveitis program

Aldeyra intends to discontinue its noninfectious anterior uveitis program after no primary or secondary endpoints were achieved in the SOLACE trial.
According to a company press release, results of the phase 3 clinical trial of topical ocular reproxalap for noninfectious anterior uveitis demonstrated no statistically significant difference in resolution rates between patients treated with the study drug and those in the vehicle-control group
“Due to high rates of disease resolution in vehicle-treated patients, no primary or secondary endpoints were achieved in the SOLACE trial,”

Full Story →